Co-Diagnostics Business Summary

Co-Diagnostics, Inc. (CODX) is a molecular diagnostics company that generates revenue through the development, manufacture, and sale of reagents and equipment utilizing its proprietary Co-Primers technology. The business is primarily segmented into infectious disease testing, including its Logix Smart line for centralized labs, and its emerging decentralized Co-Dx PCR platform designed for point-of-care (PoC) and at-home use. Revenue streams are transitioning from legacy COVID-19 testing and NIH grant funding toward a recurring model based on high-margin consumable test kits for tuberculosis, respiratory multiplex (Flu/COVID/RSV), and vector-borne illnesses. The company operates globally through strategic joint ventures, notably CoSara in India and CoMira in the MENA region, and recently integrated an AI business unit to optimize its Primer Ai design platform. Co-Diagnostics competes directly with industry giants such as Abbott Laboratories, Danaher (Cepheid), and QuidelOrtho, as well as specialized players like Novacyt. Within this landscape, CODX positions itself as a disruptive micro-cap innovator focused on democratizing high-complexity PCR accuracy through low-cost, accessible hardware. Led by co-founder Dwight H. Egan, who serves as Chairman and CEO with a background in private investment and financial data, the leadership team was significantly restructured in 2024 to support commercialization. Key executives include President Richard Abbott, a veteran of the in vitro diagnostics (IVD) industry who previously served as VP of Engineering at BioFire Diagnostics, and CFO Brian L. Brown, who oversees financial strategy following roles at Sportsman's Warehouse. The technical core is anchored by CTO and AI Officer Christopher Thurston, a co-inventor of the Co-Dx PCR platform and former architect at BioMerieux, and COO David Nielsen, who brings over 25 years of R&D leadership from BioFire. Co-founder Seth Egan serves as Chief Commercialization Officer, leveraging his experience in global distribution to scale the company’s international footprint. The company’s pedigree is further bolstered by a Scientific Advisory Board chaired by Dr. Carl Wittwer, a pioneer in rapid PCR technology, and historical backing from the NIH’s RADx program, which has been instrumental in funding the development of its decentralized testing suite.